A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Investigating Primary Thromboprophylaxis With Rivaroxaban in Patients With Malignancy and Central Venous Catheters
Phase of Trial: Phase III
Latest Information Update: 14 Aug 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Catheter thrombosis; Venous thromboembolism
- Focus Therapeutic Use
- Acronyms TRIM-Line
- 09 Aug 2019 Planned End Date changed from 31 Dec 2018 to 1 Apr 2020.
- 09 Aug 2019 Planned primary completion date changed from 31 Oct 2018 to 30 Dec 2019.
- 09 Aug 2019 Status changed from not yet recruiting to recruiting.